BACKGROUND AND AIM: Polychromatic light is actively used in medicine. However, its oncological safety and effect against cytotoxic therapy remains poorly studied. Multiple myeloma (MM) develops in the bone marrow and therefore malignant plasma cells are inaccessible to direct exposure to light. The aim of our work was to study the influence of polychromatic visible and infra-red light (pVIS + pIR) on growth and sensitivity of the myeloma cells to the cytotoxic effect of drug bortezomib (BTZ) through systemic mechanism. MATERIALS AND METHODS: We explored the effect of volunteers blood sera after their 4-daily irradiations with pVIS + pIR light (480-3400 nm) on growth and viability of the human myeloma RPMI 8226 cells in the presence of BTZ at its application in 2 modes: short-term (1 h, 300 nM) and long-term ( 96 h, 5 nM). Viability and proliferative activity of cells was evaluated by MTT assay. RESULTS: It was found that photomodified blood sera delayed growth of myeloma RPMI 8226 cells (by 25 % in 48 h and 23 % in 96 h) but had no effect on spontaneous and mitogen-induced proliferation of autologous peripheral blood T- and B-lymphocytes. We also revealed that pVIS + pIR did not change RPMI 8226 cells sensitivity to BTZ. CONCLUSION: The results suggest the systemic mechanism of polychromatic light and argue in favor of its oncological safety during/after BTZ therapy of MM patients without effect on the drug cytotoxicity. 2019, Japan Medical Laser Laboratory.
BACKGROUND AND AIM: Polychromatic light is actively used in medicine. However, its oncological safety and effect against cytotoxic therapy remains poorly studied. Multiple myeloma (MM) develops in the bone marrow and therefore malignant plasma cells are inaccessible to direct exposure to light. The aim of our work was to study the influence of polychromatic visible and infra-red light (pVIS + pIR) on growth and sensitivity of the myeloma cells to the cytotoxic effect of drug bortezomib (BTZ) through systemic mechanism. MATERIALS AND METHODS: We explored the effect of volunteers blood sera after their 4-daily irradiations with pVIS + pIR light (480-3400 nm) on growth and viability of the human myeloma RPMI 8226 cells in the presence of BTZ at its application in 2 modes: short-term (1 h, 300 nM) and long-term ( 96 h, 5 nM). Viability and proliferative activity of cells was evaluated by MTT assay. RESULTS: It was found that photomodified blood sera delayed growth of myeloma RPMI 8226 cells (by 25 % in 48 h and 23 % in 96 h) but had no effect on spontaneous and mitogen-induced proliferation of autologous peripheral blood T- and B-lymphocytes. We also revealed that pVIS + pIR did not change RPMI 8226 cells sensitivity to BTZ. CONCLUSION: The results suggest the systemic mechanism of polychromatic light and argue in favor of its oncological safety during/after BTZ therapy of MM patients without effect on the drug cytotoxicity. 2019, Japan Medical Laser Laboratory.
Authors: Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau Journal: Lancet Oncol Date: 2011-04-18 Impact factor: 41.316
Authors: Donna E Reece; Dan Sullivan; Sagar Lonial; Ann F Mohrbacher; Gurkamal Chatta; Chaim Shustik; Howard Burris; Karthik Venkatakrishnan; Rachel Neuwirth; William J Riordan; Michael Karol; Lisa L von Moltke; Milin Acharya; Peter Zannikos; A Keith Stewart Journal: Cancer Chemother Pharmacol Date: 2010-03-20 Impact factor: 3.333
Authors: Águida Cristina Gomes Henriques; Fernanda Ginani; Ruth Medeiros Oliveira; Tatjana Souza Lima Keesen; Carlos Augusto Galvão Barboza; Hugo Alexandre Oliveira Rocha; Jurema Freire Lisboa de Castro; Ricardo Della Coletta; Roseana de Almeida Freitas Journal: Lasers Med Sci Date: 2014-02-14 Impact factor: 3.161
Authors: Felipe F Sperandio; Fernanda S Giudice; Luciana Corrêa; Décio S Pinto; Michael R Hamblin; Suzana C O M de Sousa Journal: J Biophotonics Date: 2013-04-02 Impact factor: 3.207